Mr Atwill assumes the position with immediate effect. He will be based in Canberra but will split his executive time between the Company's operational headquarters in Cambridge, UK and Australia, where C3's investor base is located.
Mr Atwill is an experienced corporate executive with broad international experience in the pharmaceutical, medical device and medical services sectors. His experience includes commercialisation of innovative medical devices in international markets.
C3 Chairman Dalton Gooding said the Board was delighted to have secured a CEO of the calibre and experience of Mr Atwill.
"Bob has extensive experience in our sector and in our markets. He will bring great leadership skills and strategy implementation capabilities that will help C3 to focus on its core challenge - building sales penetration in approved markets," said Mr Gooding. "Andrew Cannon's appointment to the Board strengthens our financial management capability at the highest level in the Company and underlines our commitment to Cambridge as C3's operations headquarters."
British-born Mr Atwill was previously sales and marketing director of LSE-listed orthopaedic products manufacturer and supplier Corin Group PLC where he helped expand the business through organic growth, strategic partnerships and acquisitions.
During his time at Corin, the company's market capitalisation grew from GBP57m to GBP138m and turnover grew from GBP17m to GBP26m.
He has also worked in senior executive roles at GlaxoSmithKline and Sanofi Aventis, and was European Managing Director of Sun Healthcare Group, Inc. He has been in Australia since September 2005 and has consulted to listed biotech and biopharmaceutical companies on capital raisings and commercialisation strategies.
He has a Bachelor of Science in biochemistry from the University of Bristol and an MBA from Ashridge Management College in the UK, one of the world's leading business schools. He has also participated in Executive/President programs in the United States at Yale and UCLA.
Mr Atwill said he looked forward to his new role and to working with the C3 Board and management team.
"C3 is at an exciting stage of its development and I look forward to steering the Company through its next stage of commercialisation and achieving strong sales growth," he said. "From my experience, I believe C3 has a unique portfolio of products that have outstanding commercial potential."
"Initial feedback from many international markets has been very positive. Our challenge now is to accelerate sales penetration and to convey to the capital markets why C3 should be supported."
Further to the announcement made on 11 April 2006, Mr Troels Jordansen resigns from the Board with effect from 16 May 2006.
C3 will conduct an institutional investor roadshow in Australia during June/July. C3 will be hosting an Investor Conference call Wednesday 17 May 2006, 4.30pm Sydney time. Available to answer questions will be Chairman Dalton Gooding, CEO Bob Atwill and CFO Andrew Cannon. To participate in the investor conference call as an Australian investor please call 02 8251 8117 followed by C3's Account Number 72271780, followed by C3's Guest Pin 6125#. This electronic service only allows 30 participants.
Download AUDIO Presentation; http://www.clinicalcellculture.com/one/audio/17.05.06%20V2.mp3
About CLINICAL CELL CULTURE LIMITED
Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/ collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.
Contact: Dalton GoodingClinical Cell CultureTel: +61 (0) 8 9327 1700Email: investor@clinicalcellculture.com
Source: CLINICAL CELL CULTURE LIMITED(ASX: CCE) (ZOBEX: GCR) (EUREX: GCR) (XETRA: GCR) (PNK: CCLUF) Topic: Executive appointment Sectors: Biotech, Health & Pharm General
Copyright © 2006 ACN Network. A division of Asia Corporate News Network. All rights reserved.
